
M. tuberculosis 6 kDa early secretory antigenic target 71-78, NLARTISEA
Description
About M. tuberculosis 6 kDa early secretory antigenic target 71-78, NLARTISEA
The M. tuberculosis 6 kDa early secretory antigenic target Peptide (IEDB: 189770) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The 6 kDa early secretory antigenic target Peptide, H-NLARTISEA-OH (Uniprot: P9WNK7 aa: 71-78) from JPT is produced under strict quality control and quality management.
M. tuberculosis 6 kDa early secretory antigenic target 71-78, NLARTISEA - Specifications
- Peptide sequence: H-NLARTISEA-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for M. tuberculosis 6 kDa early secretory antigenic target 71-78, NLARTISEA
References:
Read References with JPT’s Antigen Peptides
M. tuberculosis 6 kDa early secretory antigenic target 71-78, NLARTISEA has been described in:
A broad profile of co-dominant epitopes shapes the peripheral Mycobacterium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis., PLoS One, 2013 (PMID: 23555576)
SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8<sup>+</sup> T cell activation in COVID-19 patients., Sci Immunol, 2021 (PMID: 33853928)
Documentation
Documentation for M. tuberculosis 6 kDa early secretory antigenic target 71-78, NLARTISEA
Properties
Properties of M. tuberculosis 6 kDa early secretory antigenic target 71-78, NLARTISEA
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Infection |
Layout: | Freeze-dried in glass vial |
Organism: | M. tuberculosis |
Protein Name: | 6 kDa early secretory antigenic target |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to M. tuberculosis 6 kDa early secretory antigenic target 71-78, NLARTISEA
Information | Values |
---|---|
Sequence: | H-NLARTISEA-OH |
Specifications: | 9mer peptide as TFA salt |